The World Health Organisation has named antimicrobial resistance, caused by the overuse of antibiotics and other drugs, one of the top 10 public health threats.
Less than a century after the discovery of penicillin, physicians are running out of options to treat bacterial infections. In fact, the next global pandemic could be caused by a multidrug resistant strain of a previously eradicated pathogen.
New and sustainable novel solutions are necessary to get ahead of the trajectory of antimicrobial resistance. However, it is possible to build a better understanding of the antimicrobial crisis and strengthen public health defenses. Clinical research has a key role to play in developing the needed solutions to this rising threat, and improving existing healthcare tools.
Register for the webinar to learn about the antimicrobial resistance crisis and what the biopharma and healthcare industries can do to mitigate the impact of future pandemics. Experts from ICON will discuss:
- Factors contributing to the rise of antimicrobial resistance, including climate change and industrial farming
- Why innovation and improvement in diagnostics, preventative measures and novel treatments is crucial
- The current regulatory landscape and how industry has responded
- Considerations for a successful infectious disease clinical trial, including lessons learned from the race for a COVID-19 vaccine
- Opportunities for the post-antibiotic era
On-demand webinar archive
To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.
Audience
This programme will be beneficial for:
- Pharma project management, particularly in infectious diseases
- Clinical and scientific researchers
- Academic institutions and international bodies
- Government bodies
Presenters
Shelley McLendon
Shelley has more than 25 years of clinical research experience, 19 of which are tenured at ICON. Shelley provides executive leadership and oversight for ICON’s clinical and project management teams in the implementation and execution of vaccine and infectious disease clinical development programs. She also consults with small to mid-size biotechnology clients and large pharmaceutical companies providing strategic operational guidance and driving partnership development. Shelley is a key leader of ICON’s COVID-19 Taskforce which is cross-functional team of ICON executive leaders whose mission is to make a difference by advancing research in the fight against COVID-19.
Kersten Kurt Koelsch
Kersten is a board certified internist and infectious diseases specialist with over 15 years of clinical practice and clinical research practice at University Medical Centers in Germany, the US and Australia. He has been involved in numerous Phase I – Phase III studies for antimicrobials, antivirals and vaccines resulting in many international, peer reviewed publications. Kersten joined ICON over four years ago where he is currently appointed as a Senior Medical Director and leads the medical team dedicated to infectious diseases clinical trials for the Europe and Asia-Pacific region.
Dr. Zadeikis is an internist and infectious disease specialist who after 5 years of clinical practice of infectious disease transitioned into industry. She has worked more than 20 years in both the role of medical director at medium-large pharmaceutical companies as well as medical director at contract research organisations in the field of infectious disease. Dr. Zadeikis had been at PRA/ICON for the past two and a half years and is currently a Senior Medical Director in Infectious Disease.